AbbVie received a Complete Response Letter from the FDA regarding its application for TrenibotE, a fast-acting botulinum neurotoxin serotype E for treating moderate to severe glabellar lines. The FDA's concerns were limited to manufacturing process details, with no safety or efficacy issues raised, and no additional clinical trials requested. AbbVie plans to respond to the FDA's feedback in the coming months. TrenibotE is notable for its rapid onset and shorter duration compared to existing type A botulinum toxins, potentially appealing to patients seeking shorter-term effects.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
